EARNEST Partners’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,844,621
| Closed | -$57.3M | – | 1139 |
|
|
2022
Q2 | $57.3M | Sell |
1,844,621
-226,755
| -11% | -$7.74M | 0.38% | 107 |
|
|
2022
Q1 | $85.1M | Sell |
2,071,376
-117,230
| -5% | -$5.17M | 0.5% | 82 |
|
|
2021
Q4 | $95.1M | Sell |
2,188,606
-48,575
| -2% | -$2.2M | 0.55% | 74 |
|
|
2021
Q3 | $112M | Buy |
2,237,181
+115,637
| +5% | +$7M | 0.68% | 57 |
|
|
2021
Q2 | $134M | Buy |
2,121,544
+660,477
| +45% | +$42.4M | 0.79% | 44 |
|
|
2021
Q1 | $136M | Buy |
1,461,067
+70,332
| +5% | +$7.2M | 0.81% | 40 |
|
|
2020
Q4 | $125M | Sell |
1,390,735
-4,059
| -0.3% | -$373K | 0.86% | 40 |
|
|
2020
Q3 | $144M | Sell |
1,394,794
-147,430
| -10% | -$15.9M | 1.24% | 12 |
|
|
2020
Q2 | $122M | Sell |
1,542,224
-1,240,552
| -45% | -$92.4M | 1.15% | 16 |
|
|
2020
Q1 | $161M | Buy |
2,782,776
+747,724
| +37% | +$43.1M | 1.81% | 3 |
|
|
2019
Q4 | $110M | Buy |
2,035,052
+289,599
| +17% | +$15.7M | 0.86% | 41 |
|
|
2019
Q3 | $91.3M | Buy |
1,745,453
+53,282
| +3% | +$2.48M | 0.82% | 45 |
|
|
2019
Q2 | $81.7M | Buy |
1,692,171
+1,516,013
| +861% | +$72.7M | 0.74% | 50 |
|
|
2019
Q1 | $8.9M | Buy |
+176,158
| New | +$10.4M | 0.09% | 164 |
|
|
2018
Q4 | – | Sell |
-407
| Closed | -$27K | – | 1190 |
|
|
2018
Q3 | $27K | Hold |
407
| – | – | ﹤0.01% | 381 |
|
|
2018
Q2 | $21K | Hold |
407
| – | – | ﹤0.01% | 423 |
|
|
2018
Q1 | $21K | Hold |
407
| – | – | ﹤0.01% | 418 |
|
|
2017
Q4 | $19K | Buy |
+407
| New | +$17.1K | ﹤0.01% | 426 |
|
|
2017
Q1 | – | Sell |
-407
| Closed | -$13K | – | 431 |
|
|
2016
Q4 | $13K | Hold |
407
| – | – | ﹤0.01% | 467 |
|
|
2016
Q3 | $13K | Hold |
407
| – | – | ﹤0.01% | 326 |
|
|
2016
Q2 | $11K | Hold |
407
| – | – | ﹤0.01% | 332 |
|
|
2016
Q1 | $15K | Hold |
407
| – | – | ﹤0.01% | 320 |
|
|
2015
Q4 | $16K | Hold |
407
| – | – | ﹤0.01% | 312 |
|
|
2015
Q3 | $12K | Hold |
407
| – | – | ﹤0.01% | 332 |
|
|
2015
Q2 | $13K | Hold |
407
| – | – | ﹤0.01% | 328 |
|
|
2015
Q1 | $12K | Hold |
407
| – | – | ﹤0.01% | 334 |
|
|
2014
Q4 | $11K | Hold |
407
| – | – | ﹤0.01% | 351 |
|
|
2014
Q3 | $9K | Hold |
407
| – | – | ﹤0.01% | 356 |
|
|
2014
Q2 | $9K | Hold |
407
| – | – | ﹤0.01% | 372 |
|
|
2014
Q1 | $10K | Sell |
407
-200
| -33% | -$5.05K | ﹤0.01% | 363 |
|
|
2013
Q4 | $14K | Buy |
+607
| New | +$12.7K | ﹤0.01% | 372 |
|
Other funds holding EBS
EARNEST Partners's EBS Position: Q3 2022 in Review
EARNEST Partners sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 1,844,621 shares — an estimated $57.3M sold.
EARNEST Partners first reported a position in EBS in Q4 2013 and held it in 31 quarters. The position peaked at $161M in Q1 2020. 211 funds tracked by Wall St. Rank hold EBS as of Q3 2022.
- EARNEST Partners reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
- EARNEST Partners sold 1,844,621 Emergent Biosolutions shares in Q3 2022, an estimated $57.3M.
- EARNEST Partners first reported a position in Emergent Biosolutions in Q4 2013 and held it in 31 quarters.
- EARNEST Partners's Emergent Biosolutions position peaked at $161M in Q1 2020.
- 211 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.
Based on EARNEST Partners's 13F filing for Q3 2022, filed 14 Nov 2022.